Ionis: First-In-Class drug bepirovirsen enters phase 3 clinical trials
- Is Zero-Calorie Sweetener Harmful?
- Can Collagen Effectively Fight Wrinkles and Aging?
- Hurricane Milton Brings Severe Shortage of Intravenous Solutions in US
- How can people infected with HIV keep their CD4 levels stable?
- Constipation-Related Disruption of the Intestinal Flora Also Affects the Heart
- New Research Suggests Human Lifespan May Have Reached Its Limit
Ionis: First-In-Class drug bepirovirsen enters phase 3 clinical trials
- Shocking! All existing AIDS vaccine developments have failed
- Sanofi Japan Data Breach: 730000 Healthcare Professionals’ Information Exposed
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Ionis: First-In-Class drug bepirovirsen enters phase 3 clinical trials. Clearing virus is expected to functionally cure hepatitis B.
Recently, Ionis Pharmaceuticals announced that GlaxoSmithKline has initiated two randomized, double-blind, placebo-controlled phase 3 studies to evaluate the safety and efficacy of bepirovirsen (formerly IONIS-HBVRx) in patients with chronic hepatitis B infection (CHB) sex.
GlaxoSmithKline has taken a step towards its goal of providing a functional cure for hepatitis B patients.
In 2019, GlaxoSmithKline paid Ionis an upfront payment of $25 million to obtain the latter’s license to develop bepirovirsen.
bepirovirsen (formerly IONIS-HBVRx, also known as GSK3228836), is an investigational antisense drug designed to reduce the production of the viral protein HBsAg, which is involved in hepatitis B virus (HBV) infection and replication, in both acute and chronic infections Both exist and are associated with poor prognosis in patients with chronic HBV infection.
Dr. Richard S. Geary, Executive Vice President and Chief Development Officer of Ionis, said: “The Phase 3 initiation of bepirovirsen is an important step towards delivering a novel medicine to HBV patients in need. Previously promising Phase 2b results, including the possibility of a functional cure, provide This is an early indication that bepirovirsen has the potential to provide significant benefits to patients with CHB, a serious chronic health problem.”
In a phase 2b clinical trial, bepirovirsen had undetectable virus levels in almost 30% of participants after 24 weeks of treatment.
Currently, CHB treatment is mainly based on interferon and nucleoside analogues, such as entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate.
Interferon drugs mainly strengthen the immune system, and nucleoside analogs prevent or slow down virus replication.
However, even when the two are used in combination, only a small proportion of patients have undetectable levels of HBsAg.
Therefore, the current first-line therapy for CHB patients can inhibit viral replication, but cannot clear the virus, and generally has to be taken for life.
As a potential first-in-class treatment for CHB, bepirovirsen’s unique design can simultaneously reduce the replication of hepatitis B virus and inhibit viral antigens, hoping to stimulate innate immunity and help patients achieve functional cure.
Ionis also received a $15 million milestone payment from GlaxoSmithKline related to the progress of bepirovirsen into Phase 3 clinical studies.
Ionis: First-In-Class drug bepirovirsen enters phase 3 clinical trials. Clearing virus is expected to functionally cure hepatitis B.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
